385 related articles for article (PubMed ID: 31410188)
1. Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.
Zhang Z; Gao W; Zhou L; Chen Y; Qin S; Zhang L; Liu J; He Y; Lei Y; Chen HN; Han J; Zhou ZG; Nice EC; Li C; Huang C; Wei X
Theranostics; 2019; 9(17):4878-4892. PubMed ID: 31410188
[No Abstract] [Full Text] [Related]
2. Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Spencer SA; Riley AC; Matthew A; Di Pasqua AJ
Ann Pharmacother; 2019 Jun; 53(6):621-626. PubMed ID: 30638036
[TBL] [Abstract][Full Text] [Related]
3. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
4. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
[TBL] [Abstract][Full Text] [Related]
5. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
6. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
7. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
9. Brefeldin A inhibits colorectal cancer growth by triggering Bip/Akt-regulated autophagy.
Zhou L; Gao W; Wang K; Huang Z; Zhang L; Zhang Z; Zhou J; Nice EC; Huang C
FASEB J; 2019 Apr; 33(4):5520-5534. PubMed ID: 30668917
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Hamilton G; Hochmair MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
[No Abstract] [Full Text] [Related]
12. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
13. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
14. ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation.
Gou W; Li Z; Xu X; Shen J; Guo M; Zhou X; Zhang X; Wu Y; Zhai X; Zuo D
Biochim Biophys Acta Mol Cell Res; 2020 Jul; 1867(7):118712. PubMed ID: 32224191
[TBL] [Abstract][Full Text] [Related]
15. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC.
Hoy SM
Drugs; 2021 Feb; 81(2):267-275. PubMed ID: 33528789
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer.
Cheng X; Feng H; Wu H; Jin Z; Shen X; Kuang J; Huo Z; Chen X; Gao H; Ye F; Ji X; Jing X; Zhang Y; Zhang T; Qiu W; Zhao R
Cancer Lett; 2018 Sep; 431():105-114. PubMed ID: 29859300
[TBL] [Abstract][Full Text] [Related]
17. Melatonin Induces Autophagy via Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress Pathway in Colorectal Cancer Cells.
Chok KC; Koh RY; Ng MG; Ng PY; Chye SM
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443626
[TBL] [Abstract][Full Text] [Related]
18. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
[TBL] [Abstract][Full Text] [Related]
19. Endoplasmic reticulum stress triggered by Soyasapogenol B promotes apoptosis and autophagy in colorectal cancer.
Wang L; Yun L; Wang X; Sha L; Wang L; Sui Y; Zhang H
Life Sci; 2019 Feb; 218():16-24. PubMed ID: 30553871
[TBL] [Abstract][Full Text] [Related]
20. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
